Dr. Haifeng Wang (China)
Urologist
Dr Wang has been focusing on early diagnosis, minimally invasive treatment of prostate tumors. He further studied in Japan, Germany, Hong Kong SAR and other places.
He has achieved unique research success in prostate targeted puncture, minimally invasive radical prostatectomy with nerve sparing, minimally invasive treatment of prostate tumors under the guidance of molecular imaging, precise local treatment of prostate tumors using advanced energy platform, comprehensive treatment of prostate cancer, and ultra-micro invasive treatment of prostate hyperplasia using advanced energy platform.
Dr Wang presided over 6 national key special sub projects, National Natural Science Youth Fund, Shanghai innovation action plan, Shanghai Municipal Health and Family Planning Commission fund and college fund. As the first author or corresponding author, he published over 20 SCI papers including JAMA Surgery.
In July 2022, online in JAMA surgery (if16.681, Division 1 of the literature and information center of Chinese Academy of Sciences), Dr Wang, as the first author, published Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation A Nonrandomized Controlled Trial.
For localized prostate cancer (PCA), although radiotherapy and radical prostatectomy can achieve tumor clearance, they are often accompanied by urinary incontinence, sexual dysfunction and other complications. Local treatment of PCA with high-intensity focused ultrasound, freezing, laser and photodynamic energy platforms can protect urination and erectile function, but it is difficult to achieve the optimal solution between tumor control and prostate function protection due to their technical limitations. As a new energy platform, high-frequency irreversible electroporation (h-fire) can destroy tumor cells without generating heat energy, and can selectively protect the nerve and vascular structures around the prostate. In animal experiments, it has shown better ablation effect and lower incidence of muscle spasm than the first generation irreversible electroporation (IRE), but there is no further clinical evidence.
Dr Wang cooperated with other professors teams to carry out the world's first multicenter clinical study of h-fire local treatment of prostate cancer. One arm objective behavior criteria (OPC) was used as an evaluation tool. 117 patients from May 2018 to March 2019 were selected, of whom 109 received h-fire ablation (average age 67 years). The results showed that the extensive local ablation with h-fire for PCA had good tumor control and small functional damage. The incidence of clinically significant prostate cancer (csPCA) was significantly lower than that of the previous control group with other energy platforms after a follow-up of 6 months, and the impact on prostate functions was less. The study also identified some key parameters for full ablation of h-fire.
Dr Wang's academic achievements have been widely recognized in the urology field. He actively participates in social activities. He is a member of the Urology Branch of the Chinese Medical Association and a member of the Andrology Branch of the Shanghai Medical Association.
Dr. Wang speaks Mandarin and English.
|